{"id":"NCT00166517","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"V260 Registration Study (V260-013)(COMPLETED)","officialTitle":"Immunogenicity and Safety of V260 in Healthy Infants in Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08","primaryCompletion":"2006-07","completion":"2006-07","firstPosted":"2005-09-14","resultsPosted":"2009-09-23","lastUpdate":"2015-04-01"},"enrollment":178,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Rotavirus"],"interventions":[{"type":"BIOLOGICAL","name":"Rotavirus Vaccine, Live, Oral, Pentavalent","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"Immunogenicity and Safety of V260 in Healthy Infants in Korea","primaryOutcome":{"measure":"Serum Anti-Rotavirus IgA Response","timeFrame":"Baseline and 14 days Postdose 3","effectByArm":[{"arm":"RotaTeqâ„¢","deltaMin":89,"sd":null},{"arm":"Placebo","deltaMin":7,"sd":null}],"pValues":[{"comp":"OG000","p":"0.003"}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18174862"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":114},"commonTop":["Irritability","Vomiting","Diarrhoea","Upper respiratory tract infection","Fever"]}}